Anlon Healthcare IPO will open on August 26, 2025, and close on August 29, 2025. It is a Book Built Issue through which the company aims to raise approximately ₹121.03 crores. The IPO comprises a fresh issue of ₹121.03 crores with a face value of ₹10 per share.
The Anlon Healthcare IPO price band has been set at ₹86 to ₹91 per share. The allocation quota is divided as 75% for Qualified Institutional Buyers (QIBs), 15% for High Net-Worth Individuals (HNIs), and 10% for Retail Investors. The shares are proposed to be listed on both the BSE and NSE, with a tentative listing date of September 3, 2025. The IPO allotment date is scheduled for September 1, 2025.
From a financial standpoint, Anlon Healthcare Limited reported a revenue of ₹66.69 crores in FY 2024, compared to ₹113.12 crores in FY 2023. Despite the dip in revenue, the company’s net profit improved to ₹9.66 crores in 2024, up from ₹5.82 crores in 2023.
Anlon Healthcare IPO Date & Price Band Details
The Anlon Healthcare IPO will open on August 26, 2025, and close on August 29, 2025. With a price band of ₹86 to ₹91 per share and a lot size of 164 shares, the IPO aims to raise ₹121.03 crores. Shares will list on BSE and NSE.
| Category | Details |
|---|---|
| IPO Open Date: | August 26, 2025 |
| IPO Close Date: | August 29, 2025 |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹86 to ₹91 Per Share |
| Issue Size: | Approx ₹121.03 Crores |
| Fresh Issue: | Approx ₹121.03 Crores |
| Lot Size: | 164 Shares |
| Issue Type: | Book Build IPO |
| IPO Listing: | BSE & NSE |
| Retail Quota: | Not more than 10% |
| QIB Quota: | Not more than 75% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | Click Here |
Anlon Healthcare IPO Market Lot
The Anlon Healthcare IPO minimum lot size is 164 shares, requiring a minimum investment of ₹14,924. Retail investors can apply for a maximum of 13 lots, which equals 2,132 shares with a total application amount of ₹1,94,012.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 164 | ₹14,924 |
| Retail Maximum | 13 | 2,132 | ₹1,94,012 |
| S-HNI Minimum | 14 | 2,296 | ₹2,08,936 |
| B-HNI Minimum | 68 | 11,152 | ₹10,14,832 |
Anlon Healthcare IPO Allotment & Listing Dates
The Anlon Healthcare IPO will open on August 26, 2025, and will close on August 29, 2025. The IPO allotment date is scheduled for September 1, 2025, while the listing date is fixed for September 3, 2025 on both the BSE and NSE.
| Type | Date |
|---|---|
| IPO Open Date: | August 26, 2025 |
| IPO Close Date: | August 29, 2025 |
| Basis of Allotment: | September 1, 2025 |
| Refunds: | September 2, 2025 |
| Credit to Demat Account: | September 2, 2025 |
| IPO Listing Date: | September 3, 2025 |
Anlon Healthcare IPO: Promoters
The promoters of Anlon Healthcare Limited are Punitkumar R. Rasadia, Meet Atulkumar Vachhani, and Mamata Punitkumar Rasadia. The promoter group has been instrumental in driving the company’s growth and strategic vision, ensuring a strong foundation for its future expansion.
Anlon Healthcare IPO Company Financial Report
In terms of financial performance, Anlon Healthcare Limited reported a revenue of ₹66.69 crores in FY 2024, compared to ₹113.12 crores in FY 2023. Despite the decline in revenue, the company’s net profit improved to ₹9.66 crores in 2024, as against ₹5.82 crores in 2023, showing better profitability and operational efficiency.
| Period Ended | Revenue | Expense | PAT | Assets |
|---|---|---|---|---|
| 2022 | ₹57.54 | ₹57.64 | ₹0.11 | ₹84.97 |
| 2023 | ₹113.12 | ₹106.13 | ₹5.82 | ₹111.55 |
| 2024 | ₹66.69 | ₹56.94 | ₹9.66 | ₹128.00 |
| 2025 | ₹120.46 | ₹93.57 | ₹20.52 | ₹181.30 |
Anlon Healthcare IPO Valuation – FY2025
| KPI | Values |
|---|---|
| ROE: | 25.51% |
| ROCE: | 21.93% |
| EBITDA Margin: | 26.88% |
| PAT Margin: | 17.06% |
| Debt to equity ratio: | 0.73 |
| Earning Per Share (EPS): | ₹6.38 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 25.51% |
| Net Asset Value (NAV): | ₹20.18 |
Anlon Healthcare IPO Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Kronox Lab Sciences Limited | 5.81 | 26.72 | 32.20 | 17.87 | 91.44 Cr. |
| AMI Organics Limited | 11.91 | 197.70 | 6.47 | 183.05 | 701.37 Cr. |
| Supriya Lifeciences Limited | 14.80 | 49.52 | 14.61 | 101.31 | 581.01 Cr. |
Objects of the Issue – Anlon Healthcare IPO
The net proceeds from the Anlon Healthcare IPO will be utilized for the following purposes:
- Funding capital expenditure requirements for the company’s proposed expansion projects.
- Repayment or prepayment (full or part) of certain outstanding secured borrowings, including term loans availed by the company.
- Meeting working capital requirements to support day-to-day business operations.
- General corporate purposes, including strategic initiatives, brand strengthening, and overall business growth.
Anlon Healthcare Company Overview, Strengths, and Risks
Anlon Healthcare is a chemical manufacturing company founded in 2013, specializing in high-purity pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs). Its products are used in finished dosage forms like tablets, capsules, and syrups, as well as in nutraceuticals, personal care, and veterinary products.
The company’s portfolio includes 65 commercialized products, with a strong pipeline of 28 products at the pilot stage and 49 in laboratory-scale testing. Anlon’s manufacturing facility in Rajkot, Gujarat, has an installed capacity of 400 MTPA, with a new 700 MTPA plant planned for expansion.
Anlon Healthcare serves clients in over 15 countries, including Italy, Germany, and Japan, and its products comply with major international pharmacopoeia standards like IP, BP, EP, JP, and USP. The company has also received Drug Master File (DMF) approvals from international regulators, which is crucial for entering regulated markets.
Strengths
- Strong Product Portfolio and Pipeline: The company has a diversified range of commercial products and a significant pipeline of new products in development, which ensures future revenue streams and reduces dependence on a single product.
- High Entry Barriers: The pharmaceutical intermediates and API market has high entry and exit barriers due to lengthy customer approval cycles, stringent quality standards, and regulatory requirements. This “customer stickiness” provides Anlon with repeat orders and long-term partnerships.
- Regulatory Credibility: Anlon has secured multiple DMF approvals from key international bodies like ANVISA (Brazil), NMPA (China), and PMDA (Japan), which enhances its credibility and opens doors to higher-margin export markets.
- Strong Financial Performance: The company has shown significant growth in recent years. Its profit after tax (PAT) has increased consistently from ₹5.82 crore in FY23 to ₹20.52 crore in FY25. The company’s balance sheet has also strengthened, and it has successfully deleveraged its debt.
- Scalable Business Model: With a new 700 MTPA plant in the works, Anlon is poised to significantly increase its manufacturing capacity, which is crucial for future growth and meeting rising demand.
- Focus on Quality and Sustainability: The company maintains a strong focus on quality with four in-house laboratories and has a “zero-liquid discharge” facility, reflecting its commitment to environmental responsibility.
Risks
- Customer Concentration: A major risk is the high dependence on a few key clients. The top 10 customers contributed between 75% and 78% of the company’s revenue from FY23 to FY25. The loss of a single major customer could significantly impact the business.
- Negative Operating Cash Flows: The company has experienced negative operating cash flows in recent years, which indicates a working capital-intensive business model. This could strain its cash flow if not managed effectively, although a portion of its IPO proceeds is planned to address this.
- Geographic and Operational Concentration: Anlon’s revenues are largely domestic (India-centric), with exports accounting for only a small portion of sales despite its DMF filings. Additionally, all its operations are concentrated in a single facility in Rajkot, Gujarat, making it vulnerable to any regional or operational disruptions.
- Regulatory and Compliance Risks: The pharmaceutical and chemical industry is heavily regulated. Any failure to comply with strict technical specifications, quality standards, or a delay in receiving new regulatory approvals could negatively impact business and lead to the cancellation of orders.
- Market and Price Volatility: The demand for APIs and intermediates can be cyclical, and the company is exposed to fluctuations in raw material prices and intense competition from domestic and international players, which can affect profitability.
Anlon Healthcare IPO Review
- Canara Bank
- DRChoksey FinServ
- Emkay Global
- Hem Securities
- IDBI Capital
- Marwadi Shares
- Nirmal Bang
- SBICAP Securities
- Sharekhan
- SMC Global
- Sushil Finance
- Swastika Investmart
- Ventura Securities
- Geojit
- Reliance Securities
- Capital Market
- BP Wealth
- ICICIdirect
- Choice Broking
Anlon Healthcare IPO Registrar
KFin Technologies Limited
Phone: 04067162222, 04079611000
Email: ahl.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/
Anlon Healthcare IPO Lead Managers aka Merchant Bankers
- Interactive Financial Services Ltd
Anlon Healthcare Company Address
Anlon Healthcare Ltd.
101/102, Silvercoin Complex,
Opp.Crystal Mall,
Kalawad Road,
Rajkot, Gujarat, 360005
Phone: +91 281 2562538
Email: cs@anloncro.com
Website: http://www.anlon.in/
FAQs about Anlon Healthcare IPO
The Anlon Healthcare IPO will open for subscription on August 26, 2025, and close on August 29, 2025.
The price band has been set at ₹86 to ₹91 per share.
The minimum lot size for retail investors is 164 shares, requiring an investment of ₹14,924. The maximum for retail investors is 13 lots, or 2,132 shares, for a total of ₹1,94,012.
The IPO allotment date is scheduled for September 1, 2025.
The shares are tentatively scheduled to be listed on both the BSE and NSE on September 3, 2025.
The company aims to raise approximately ₹121.03 crores through a fresh issue of shares.
The allocation is divided as follows: 75% for Qualified Institutional Buyers (QIBs), 15% for High Net-Worth Individuals (HNIs), and 10% for Retail Investors.
Anlon Healthcare is a chemical manufacturing company specializing in high-purity pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs).
In FY 2024, the company reported a revenue of ₹66.69 crores, a decrease from the previous year. However, its net profit improved significantly to ₹9.66 crores from ₹5.82 crores in FY 2023, indicating better profitability.
Some key risks include a high dependence on a few major customers (top 10 customers contributed 75-78% of revenue from FY23 to FY25), negative operating cash flows in recent years, and a single-facility operational concentration in Rajkot, Gujarat.
Disclaimer: This content is provided strictly for educational and informational purposes only. The securities or investments mentioned are based on publicly available information and should not be construed as investment advice or recommendations. Investors are advised to consult with their financial advisor before making any investment decisions.
